NCT06677788View on ClinicalTrials.gov

Evaluating the Efficacy and Safety of Roflumilast in Patients with NASH

PHASE2CompletedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

April 1, 2022

Primary Completion Date

September 20, 2024

Study Completion Date

October 15, 2024

Conditions
Non-Alcoholic Steatohepatitis (NASH)
Interventions
DRUG

Roflumilast 500 Mcg Oral Tablet

Patients in this group received roflumilast 500 μg once daily for three months.

DRUG

Vitamin E capsule

vitamin E group or control group (n=24) which received vitamin E 1000 mg once daily

Trial Locations (1)

6620010

Tanta University, Tanta

All Listed Sponsors
lead

Tanta University

OTHER